Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073177 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 819
- Enrollment target
NCT00073177 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 819 participants.
The verdict
NCT00073177, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 819 participants
- Enrollment target
Study Summary
The aim of the study is to compare the effects of oral roflumilast with placebo on lung function in patients with asthma.
Interventions
- DRUG Roflumilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 819 participants |
| Start Date | 2003-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073177
The ClinicalTrials.gov registry entry for NCT00073177 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 819 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Roflumilast is the first listed.
NCT00073177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073177 about?
NCT00073177 is a clinical study titled "Efficacy and Safety of Roflumilast in Patients With Asthma (BY217/M2-012)". The aim of the study is to compare the effects of oral roflumilast with placebo on lung function in patients with asthma.
What is the current status of trial NCT00073177?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 819 participants. The study started on 2003-11.
What interventions are being tested in trial NCT00073177?
The interventions under investigation include: Roflumilast (DRUG).
Who is sponsoring clinical trial NCT00073177?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.